Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.54 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 6/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.40 |
| ▸ | LCK | P06239 | 3/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30467909 | 1.00 | EGFR (0.54) | EGFRKDRMKNK2MKNK1LCK | |
| SCHEMBL19707904 | 0.89 | EGFR (0.43) | EGFRKDRMKNK2MKNK1 | |
| SCHEMBL28392219 | 0.89 | EGFR (0.46) | EGFRKDRMKNK2MKNK1LCK | |
| SCHEMBL20610525 | 0.89 | EGFR (0.46) | EGFRKDRMKNK2MKNK1CCNT1 | |
| SCHEMBL19337191 | 0.89 | EGFR (0.43) | EGFRKDRMKNK2MKNK1CCNT1 | |
| SCHEMBL21265492 | 0.88 | CCNT1 (0.46) | EGFRKDRMKNK2MKNK1LCK | |
| SCHEMBL30647338 | 0.88 | CCNT1 (0.46) | EGFRKDRMKNK2MKNK1LCK | |
| SCHEMBL19337070 | 0.87 | EGFR (0.43) | EGFRKDRMKNK2MKNK1CCNT1 | |
| SCHEMBL19089467 | 0.85 | KDR (0.44) | EGFRKDR | |
| SCHEMBL30930115 | 0.85 | KDR (0.43) | EGFRKDRMKNK2MKNK1CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | INVENTISBIO CO LTD (CN) | 2024-06-27 | — | — | US | disclosed |
| CN-111892579-B | Kinase inhibitors | 上海艾力斯医药科技股份有限公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-111875585-B | Kinase inhibitors | 上海艾力斯医药科技股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-111892579-A | Kinase inhibitor | 上海复尚慧创医药研究有限公司 | 2020-11-06 | — | — | CN | disclosed |
| CN-111875585-A | Kinase inhibitor | 上海复尚慧创医药研究有限公司 | 2020-11-03 | — | — | CN | disclosed |
| CN-106660993-B | Kinase inhibitor | 上海复尚慧创医药研究有限公司 | 2020-09-11 | — | — | CN | disclosed |
| US-20170355696-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | InventisBio Co., Ltd. (CN) | 2017-12-14 | — | — | US | disclosed |
| US-20170355696-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | InventisBio Co., Ltd. (CN) | 2017-12-14 | — | — | US | disclosed |
| EP-3216786-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | Shanghai Shaletech Technology Co., Ltd. (CN) | 2017-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | EGFR, WEE1, DPYD | EGFR 1/4885KDR 41/4885MKNK2 4665/4885 |
| US-20170355696-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | EGFR, WEE1, DPYD | EGFR 1/4885KDR 39/4885MKNK2 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.